#USA #New York #Levi & Korsinsky #class action lawsuit #Replimune Group

Attention Replimune Group Inc. Investors: Class Action Lawsuit Details

Levi & Korsinsky, LLP has recently informed investors of a significant class action lawsuit involving Replimune Group, Inc. (NASDAQ: REPL), pinpointing an impending deadline for lead plaintiff submissions on October 5, 2026. This alert primarily addresses shareholders who acquired REPL securities between October 20, 2025, and April 10, 2026. The lawsuit particularly involves allegations of misleading statements made by the company regarding its RP1 biologics license resubmission.

Background on the Allegations

During the class period, shares of Replimune Group peaked at $10.73 on December 8, 2025, before plummeting to a closing price of $1.70 by April 13, 2026. This decline signifies a staggering loss of approximately 84.16%, equating to a decrease of $9.03 per share.

The lawsuit names Sushil Patel, the Chief Executive Officer, and Emily Hill, the Chief Financial Officer, as individual defendants. They are accused of failing to disclose critical unresolved concerns related to an FDA study-design for the RP1 product, which they allegedly knew about while still making positive public representations regarding the company's filings with the Securities and Exchange Commission (SEC).

Legal Framework of the Case

The class action incorporates claims under various aspects of the Securities Exchange Act of 1934, notably Section 20(a), which seeks to hold individuals accountable for omissions and misstatements in formal public disclosures. This means the two executives, despite their authority, did not rectify information that was later proven to be misleading. The complaint emphasizes that they certified filings under the Sarbanes-Oxley Act, which promised accurate disclosures, yet overlooked critical FDA communications concerning unresolved study-design issues.

Potential Impact on Investors

For investors, the implications of this lawsuit are profound. Those purchased REPL shares within the designated time frame and incurred financial losses might still be eligible to recuperate their investments. Even individuals who have already sold their REPL shares could recover losses, depending on their purchase dates.

It's essential for affected investors to act quickly as the window for submitting claims closes on October 5, 2026. Individuals interested in potentially becoming lead plaintiffs or those seeking further clarity about their potential recovery options are encouraged to contact Levi & Korsinsky directly.

FAQs Regarding the REPL Lawsuit

1. Who are the Defendants?
Replimune Group, Inc. is the primary defendant alongside its senior executives who certified SEC filings.
2. What Misstatements Are Alleged?
The lawsuit claims that the company misrepresented its interaction with the FDA about its biologics application, failing to mention outstanding concerns.
3. Where Was the Lawsuit Filed?
The action was lodged in the United States District Court for the District of Massachusetts, adhering to the Private Securities Litigation Reform Act.
4. What is a Lead Plaintiff?
This is the investor who represents the entire class of claimants. The court typically selects the one who has sustained the largest loss.
5. Do I Need to Testify?
Generally, class members don't have to bear the burden of attending court or giving testimonies. Most settlement processes involve submitting a claim form.
6. What Costs Are Involved?
Engaging in this process comes at no upfront cost, as most lawsuits operate on a contingency fee basis, pending court approval.

Conclusion

The Replimune Group, Inc. class action lawsuit is a critical moment for shareholders seeking restitution for their investments. As the situation unfolds, investors are urged to stay informed and act promptly to ensure they do not miss the opportunity to recover potential losses. To discuss eligibility or legal representation, consider reaching out to Levi & Korsinsky LLP to explore your rights and options as affected shareholders.